Protective effects of Rho kinase inhibitor fasudil on rats with chronic kidney disease

American Journal of Physiology - Renal Physiology

Volumn 304, Issue 11, 2013, Pages 1325-1334

  Kushiyama, Taketoshi ^a   Oda, Takashi ^a   Yamamoto, Kojiro ^a   Higashi, Keishi ^a   Watanabe, Atsushi ^a   Takechi, Hanako ^a   Uchida, Takahiro ^a   Oshima, Naoki ^a   Sakurai, Yutaka ^a   Miura, Soichiro ^a   Kumagai, Hiroo ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin receptor blocker; Chronic kidney disease; Macrophage; Podocyte; Rho kinase inhibitor

Indexed keywords

CD68 ANTIGEN; F ACTIN; FASUDIL; NEPHRIN; OLMESARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG MEGADOSE; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; MACROPHAGE; NONHUMAN; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION; STAINING; WESTERN BLOTTING;

EID: 84878640711     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00447.2012     Document Type: Article

References (36)

1. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68: 2823-2828, 2005.
2. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 44: 874-877, 2001.
3. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
4. De Petris L, Hruska KA, Chiechio S, Liapis H. Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrol Dial Transplant 22: 3442-3450, 2007.
5. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65: 2309-2320, 2004.
6. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7: 2495-2508, 1996.
7. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delf-gaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14: 931-938, 2008.
8. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 3: 23-35, 2003.
9. Imai Y, Matsumura H, Miyajima H, Oka K. Serum and tissue lipids and glomerulonephritis in the spontaneously hypercholesterolemic (SHC) rat, with a note on the effects of gonadectomy. Atherosclerosis 27: 165-178, 1977.
10. Ishikawa Y, Nishikimi T, Akimoto K, Ishimura K, Ono H, Matsuoka H. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension 47: 1075-1083, 2006.
11. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y, Saruta T. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrecto-mized spontaneously hypertensive rats. Kidney Int 64: 2009-2019, 2003.
12. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 33: 1004-1010, 1999.
13. Kikuchi Y, Yamada M, Imakiire T, Kushiyama T, Higashi K, Hyodo N, Yamamoto K, Oda T, Suzuki S, Miura S. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol 192: 595-603, 2007.
14. Koga H, Ichijo K, Shibuya T. Acute toxicity study of fasudil hydrochlo-ride (HA-1077, AT-877) in mice and rats. Jpn Pharmacol Ther 20, Suppl 6: 1433-1439, 1992.
15. Komers R, Oyama TT, Beard DR, Tikellis C, Xu B, Lotspeich DF, Anderson S. Rho kinase inhibition protects kidneys from diabetic ne-phropathy without reducing blood pressure. Kidney Int 79: 432-442.
16. Kondo S, Yoshizawa N, Wakabayashi K. Natural history of renal lesions in spontaneously hypercholesterolemic (SHC) male rats. Nihon Jinzo Gakkai Shi 37: 91-99, 1995.
17. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148: 30-48, 2008.
18. Kushiyama T, Oda T, Yamada M, Higashi K, Yamamoto K, Sakurai Y, Miura S, Kumagai H. Alteration in the phenotype of macrophages in the repair of renal interstitial fibrosis in mice. Nephrology (Carlton) 16: 522-535.
19. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139: 137-147, 2003.
20. Loirand G, Rolli-Derkinderen M, Pacaud P. RhoA and resistance artery remodeling. Am J Physiol Heart Circ Physiol 288: H1051-H1056, 2005.
21. Lowik MM, Groenen PJ, Levtchenko EN, Monnens LA, van den Heuvel LP. Molecular genetic analysis of podocyte genes in focal seg-mental glomerulosclerosis-a review. Eur J Pediatr 168: 1291-1304, 2009.
22. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117: 175-184, 2007.
23. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 23: 344-346, 2005.
24. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686, 2004.
25. Nishikimi T, Akimoto K, Wang X, Mori Y, Tadokoro K, Ishikawa Y, Shimokawa H, Ono H, Matsuoka H. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 22: 1787-1796, 2004.
26. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, Eddy AA. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60: 587-596, 2001.
27. Oda T, Yoshizawa N, Takeuchi A, Nakabayashi I, Nishiyama J, Ishida A, Tazawa K, Murayama M, Hotta O, Taguma Y. Glomerular proliferating cell kinetics in acute post-streptococcal glomerulonephritis (APSGN). J Pathol 183: 359-368, 1997.
28. Omasu F, Oda T, Yamada M, Yoshizawa N, Yamakami K, Sakurai Y, Miura S. Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats. Am J Physiol Renal Physiol 293: F1292-F1298, 2007.
29. Peng F, Wu D, Gao B, Ingram AJ, Zhang B, Chorneyko K, McKenzie R, Krepinsky JC. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 57: 1683-1692, 2008.
30. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest 118: 3522-3530, 2008.
31. Rodriguez-Iturbe B, Sato T, Quiroz Y, Vaziri ND. AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomer-ulosclerosis in the Imai rat. Kidney Int 66: 668-675, 2004.
32. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic protein-uria. Lancet 354: 359-364, 1999.
33. Shibata S, Nagase M, Fujita T. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 17: 754-764, 2006.
34. Yamada M, Oda T, Higashi K, Kushiyama T, Yamakami K, Sakurai Y, Hirai Y, Yamamoto K, Hyodo T, Suzuki S, Miura S, Kumagai H. Involvement of epimorphin in the repair of experimental renal fibrosis in mice. Lab Invest 90: 867-880.
35. Yang Y, Guo L, Blattner SM, Mundel P, Kretzler M, Wu C. Formation and phosphorylation of the PINCH-1-integrin linked kinase-alpha-parvin complex are important for regulation of renal glomerular podocyte adhesion, architecture, and survival. J Am Soc Nephrol 16: 1966-1976, 2005.
36. Yoshikawa Y, Yamasaki K. Renal lesions of hyperlipidemic Imai rats: a spontaneous animal model of focal glomerulosclerosis. Nephron 59: 471-476, 1991.